Prosecution Insights
Last updated: November 20, 2026

George W Kosturko, USPTO Patent Examiner

Listed by the USPTO as KOSTURKO, GEORGE W

Tech Center 1600 • Art Units: 1621 1628

This examiner grants 55% of resolved cases

Analysis

KOSTURKO, GEORGE W has resolved 736 cases in Tech Center 1600 and art unit 1621. The allowance rate is 54.6%, and the median time to allowance is 995 days. The interview lift is 48.9%, showing a strong association between interviews and allowance outcomes.

The represented companies include Genentech Inc., Hoffmann-La Roche Inc., and The Regents of the University of Michigan. The leading firms are Casimir Jones, S.C., DERGOSITS & NOAH LLP, and Giordano Law LLC. The substantial record supports giving the interview figure significant weight, particularly where written prosecution alone has not resolved the key issues.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

54.6%
Allow Rate
-5.4% vs TC avg
782
Total Applications
+48.9%
Interview Lift
995
Avg Prosecution Days
Based on 736 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
15.4%
§102 Novelty
40.5%
§103 Obviousness
24.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18817828 TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT Non-Final OA Genentech, Inc.
18702989 CRYSTALLINE FORMS OF QUINAZOLINE DERIVATIVES, PREPARATION, COMPOSITION AND USE THEREOF Non-Final OA Hoffmann-La Roche Inc.
18271102 METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO T CELL MEDIATED INTESTINAL DISORDERS Final Rejection The Regents of the University of Michigan
18800173 CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY Non-Final OA Boehringer Ingelheim International GmbH
18790166 ANTIVIRAL COMPOSITIONS AND METHODS FOR INACTIVATING NON-ENVELOPED VIRUSES USING ALKYL 2-HYDROXYCARBOXYLIC ACIDS Non-Final OA ECOLAB USA INC.
18643207 PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS Final Rejection Vertex Pharmaceuticals Incorporated
18854031 LRRK2 Inhibitors Non-Final OA Brenig Therapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner George W Kosturko's allowance rate?

54.6% of resolved applications examined by George W Kosturko were allowed (736 resolved cases), compared with 46.7% across Art Unit 1621 over the last five years.

Does an interview help with examiner George W Kosturko?

This examiner's interview lift is +48.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner George W Kosturko take to allow a patent?

Applications allowed by George W Kosturko took 995 days on average from filing to allowance.

Which art unit does examiner George W Kosturko work in?

George W Kosturko examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month